Bio Association - Konkuk University Hospital, investment briefing for promising bio companies in clinical technology

Announcement of 5 bio companies specializing in promising clinical technology within 3 years of establishment

The Korea Bio Association (Chairman Seo Jeong-seon) will hold the 3rd Golden Seeds Challenge, an investment briefing session for early bio companies, in collaboration with Konkuk University Hospital at Konkuk University Biomedical Science Research Center from 1:30 pm on the 27th.

This event was prepared to promote investment in bio companies specializing in excellent clinical technology within 3 years of establishment, and to help revitalize Konkuk University Hospital's start-up through joint progress with Konkuk University Hospital.

Four biopharmaceutical fields and one digital healthcare field, which can be linked with hospitals through prior screening, will hold company briefing sessions. □ Shin Chan-yeong, CEO of Neuroventi, a development company for autism and ADHD treatment □ Kim Min-seon, CEO of Primeora, a dementia prevention and diagnosis care solution company □ Park Young-min, CEO of Dandi Bioscience, a development company for sepsis and high-risk influenza treatment □ Amtics Bio, a company specializing in probiotics and food ingredients Lee Jong-seung, CEO of □ Gill Young-joon, CEO of Huinno, a developer of electrocardiogram measurement wearable terminals, will be in charge of the presentation.

The review was conducted by four professional VCs, Gil-tae Wie, Senior Investigator at Mirae Asset Venture Investment, Chang-wan Joo, Team Leader at Kolon Investment, Seung-wook Jung, Deputy Head at Hyundai Technology Investment, Deputy Head Seong-rak Choi at Intervest, Professor Kyu-joong Ahn at the Department of Dermatology at Konkuk University Hospital, Professor Han-Young Kim at the Department of Neurology, and Hyun-kyun Ki at the Department of Infectious Diseases. Professor, Cardiovascular Medicine Professor Kim Hyun-joong is in charge of the clinical review.

Meanwhile, as an opening event, Jung Hyung-min, CEO of Mirae Cell Bio, a former entrepreneur from CHA Biotech, will give a special lecture by experts on his experience in starting a company specializing in cell therapy products and the development of new treatments.

Ban Jae-bok, head of the Korea Bio Association’s bio-entrepreneurship unit who planned this event, said, “This event was prepared as part of the association’s Startup 1000 program, focusing on clinical-specialized technology startups and receiving practical evaluations from clinical specialists at Konkuk University Hospital. It was prepared to provide an opportunity to see it.” He also said, “We plan to expand the linkage with Konkuk University Hospital and technology startups for clinical use by taking this event as an opportunity.”

Meanwhile, as a pre-event on the day, they signed a business agreement with Konkuk University and promised exchanges for bio/medical start-up accelerating and hospital start-up.